Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Androgen (Male Sex Hormone)

Testosterone (Replacement)

Brand names: Testogel, Nebido (IM), Testim gel, Tostran gel

Testosterone replacement is used for confirmed male hypogonadism only. It is not appropriate for age-related symptoms in the absence of biochemical hypogonadism.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

US labelling (FDA)

Reference — US labelling, may differ from UK

DOSAGE AND ADMINISTRATION Prior to initiating, TESTOPEL ® (testosterone pellets) confirm the diagnosis of hypogonadism by ensuring that serum testosterone concentrations have been measured in the morning on at least two separate days and that these serum testosterone concentrations are below the normal range. The suggested dosage for androgens varies depending on the age, and diagnosis of the individual patient. Dosage is adjusted according to the patient’s response and the appearance of adverse reactions. The dosage guideline for the testosterone pellets for replacement therapy in androgen-deficient males is 150mg to 450mg subcutaneously every 3 to 6 months. Various dosage regimens have …

Source: US FDA prescribing information (openFDA / DailyMed), label dated 2025-07-17. Accessed 2026-06-12. US dosing and indications can differ from UK practice — use UK sources for prescribing decisions.

Clinical monograph

How it works

It replaces endogenous testosterone, acting on androgen receptors to restore male secondary sexual characteristics and physiological androgen effects.

Prescribing in practice

  • Confirm low morning testosterone on more than one occasion before starting; it is contraindicated in prostate or male breast cancer.
  • Monitor haematocrit because of the risk of polycythaemia.
  • Assess prostate status and PSA before and during treatment.

Monitoring

Monitor testosterone levels, haematocrit and prostate health (including PSA), with clinical review of response and adverse effects.

Counselling the patient

  • This treatment is for a diagnosed testosterone deficiency, not for normal ageing.
  • Attend for blood tests to check your red cell count and prostate marker.
  • Report difficulty passing urine or other prostate symptoms.

Evidence & guidelines

Indicated for biochemically confirmed male hypogonadism per the SPC and specialist guidance.

Reference: European Association of Urology (EAU) Guidelines on Male Hypogonadism 2022; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways